The biotechnology industry has been dominated by blue chip pharmaceutical companies like Celegne, Amgen, Novartis and Pfizer for long. But there are other biotech companies who are fast rising and may soon catch up with the giants. Biotech companies mostly grow as a result of developing new drugs and thereby diversifying their portfolio, or strategic acquisitions and mergers.  Here are the ones with the biggest potentials;

Gilead Science (GILD)

Though recognized as blue chip, Gilead’s growth seems to be taking a new path upward with the development of Harvoni and Sovaldi, hepatitis C treatment drugs. Ranked as 118th in Fortune’s 500 list, these two drugs seem to be part of the 24billion dollar revenue and annual growth of at least 28% recorded over the last 5 years. The drugs, though quite high cost and outrageously expensive as some may describe them, have also been impressively effective.

Actavis (ACT)

With the acquisition of Allergan Inc. in March of 2015, the stock prices of Actavis’ shares rose. An exponential growth that was projected is slowly actualizing. With brands like Botox under their name, the company’s growth pattern is exclusively an upward one.

Pacira Pharmaceuticals (PCRX)

According to the Motley Fool, Pacira Pharmaceuticals has a forecast Earnings per Share (EPS) growth rate of 77% for the next 5 years. That is way above the average 45% percent for biotech stocks.

Pacira’s flagship medicine is Exparel, which is an anesthetic administered during or before surgery, childbirth or as a post-surgical pain relief medicine. Wall Street estimates that this one drug could rake in up to $1,000,000,000 in sales for Pacira.

Ligand Pharmaceuticals (LGND)

Ligand pharmaceuticals produce drugs that regulate genetic processes, especially in cancer cells. In the second quarter of 2015, it announced a global license and supply contract with Sanofi. Sanofi is one of the top five largest pharmaceutical companies, ranked according to prescription sales/Captisol, Ligand’s patented cyclodextrin is to be used to advance the working of Sanofi’s SAR125844. Under this agreement, Ligand is entitled to receive royalties and revenue from sales of Captisol.

In the same year, Ligand Pharmaceuticals posted a high Earnings Surprise Prediction (ESP) figure on Zack’s rank. (As interpreted by Zack’s investment research, a company that focuses on equities earnings estimates and stock analysis) In the third quarter of 2014, Ligand’s ESP was at +30.00% and was a Zack rank 1, making it a strong buy. This was higher than Pfizer’s rank, at +1.82% and a Zack’s rank #3.

Acadia Pharmaceuticals (ACAD)

Stock prices for Acadia have been soaring mainly because of the Parkinson disease focused drug that the company has been working on getting approved by FDA. Nuplazid, the drug, has been submitted for approval to the FDA, and it is widely hoped that it will be an effective treatment for Parkinson’s.

Stock prices have been rising ever since the announcement of the submission, boding well for the future of the drug and Acadia as a whole. It looks like Acadia is going to enjoy a monopoly in the market with Nuplazid, since it is currently the only drug that the FDA has approved for Parkinson breakthrough therapy.

Supernus Pharmaceuticals Inc. (SUPN)

In 2015, Deloitte ranked Supernus 4th in its annual North America Technology Fast 500. The revenue growth from 2011 to 2014 was 15.099%. It took the lead in the biotech/pharmaceutical sector, attributed to sales of Trokendi XR and Oxteller XR which treat epilepsy. Motley fool explained that the prescriptions of Trokendi increased by a whopping 187% yearly. The company is also venturing into ADHD treatment, a move that is set to spike its revenue even further.